IL13 and asthma: Accumulating evidence from ex vivo studies as well as AR or asthma animal models lend credence to the further assessment of IL-4/IL-13-targeted therapy in AR and asthma patients (Bourdin et al., 2021; Conde et al., 2021; Harb & Chatila, 2020; Russkamp et al., 2019).